Talking
Explore the symptoms your patients may experience1
Tracking changes with the MG-ADL scale1,2
The MG-ADL scale is an easy-to-use tool that assesses the impact of gMG on your patients' daily functions by measuring 8 signs or symptoms that are commonly affected in gMG. Each sign or symptom is assessed on a 4-point scale, where 0 represents normal function and 3 represents the most severe impairment of that function. A total MG-ADL score ranges from 0 to 24, with higher scores indicating more impairment.1-4
Every point on the scale matters, with a 2-point reduction indicating clinically meaningful improvement in daily functions. For example, a 2-point difference can look like1,2:
- Frequent choking necessitating changes in diet to normal function
- Shortness of breath at rest to normal breathing
- Experiencing double vision daily to not experiencing it at all
When used consistently, the MG-ADL scale acts as a tool to track measurable trends over the course of a patient's disease progression.2
See the impact of each point on the MG-ADL scale with this interactive tool.
gMG=generalized myasthenia gravis; MG-ADL=Myasthenia Gravis Activities of Daily Living.
Depicting 1 out of 8 signs and symptoms measured on the MG-ADL scale for swallowing
What could life look like with an MG-ADL score of 0 or 1?
MG-ADL=Myasthenia Gravis Activities of Daily Living; MSE=Minimal Symptom Expression.
—Jeffrey Rosenfeld, MD, PhD
Medical Director, The Center for Restorative Neurology
Loma Linda, CA
MG-ADL=Myasthenia Gravis Activities of Daily Living.
Lowering patient scores could raise the bar on outcomes3
One study of 45 patients found that scores on the Myasthenia Gravis-Quality of Life 15 (MG-QOL15), a self-reported scale designed to assess patients’ quality of life and experience with MG, correlated significantly with the scores on the MG-ADL scale and other clinical evaluation scales at all visits.* A patient with a low total MG-ADL score may still be struggling. In fact, a score of 5 may appear low but can comprise subscores of 2 and 3, indicating a less than normal or complete loss of ability to perform a daily function. Therefore, aiming to decrease even a low total score through treatment strategies may lead to improvement with daily living activities.1,3,4
Using the MG-ADL scale in clinical evaluation may not only empower your patients to get involved in their treatment journey, but may also inform your treatment decisions.3
*Data was collected from 45 patients who were starting first-time immunomodulatory treatment for MG and did not have other medical conditions that would interfere with treatment with prednisone or IVIG or that the investigator considered important. Pregnant or breastfeeding individuals were excluded.3
IVIG=intravenous immunoglobulin; MG=myasthenia gravis; MG-ADL=Myasthenia Gravis Activities of Daily Living.
References: 1. Wolfe GI et al. Neurology. 1999;52(7):1487-1489. doi:10.1212/wnl.52.7.1487 2. Muppidi S et al. Muscle Nerve. 2022;65(6):630-639. doi:10.1002/mus.27476 3. Diez Porras L et al. J Clin Med. 2022;11(8):2189. doi:10.3390/jcm11082189 4. Saccà F et al. Eur J Neurol. 2023;30(12):3854-3867. doi:10.1111/ene.15872
For US audiences only. © 2024 argenx US-UNB-24-00043 V2 07/2024. All Rights Reserved.
We’ll be in touch!
An argenx representative will contact you soon, so keep an eye on your inbox.
Thank you for signing up!
We’re looking forward to sharing information about innovations in gMG with you. Keep an eye on your inbox for important updates on Raising the Bar in gMG.
gMG=generalized myasthenia gravis.